Inspirna Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Inspirna's estimated annual revenue is currently $3.1M per year.(i)
  • Inspirna's estimated revenue per employee is $77,500

Employee Data

  • Inspirna has 40 Employees.(i)
  • Inspirna grew their employee count by 21% last year.

Inspirna's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Co-founder & AdvisorReveal Email/Phone
3
CFO & COOReveal Email/Phone
4
VP, ResearchReveal Email/Phone
5
SVP Clinical DevelopmentReveal Email/Phone
6
Head Business DevelopmentReveal Email/Phone
7
VP Finance & AccountingReveal Email/Phone
8
SVP, Chemistry & Pharmaceutical SciencesReveal Email/Phone
9
VP, ResearchReveal Email/Phone
10
Senior Director Clinical Data ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-20%N/AN/A
#2
$6.7M438%N/AN/A
#3
$34.4M222-1%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.3M2-50%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$3.6M230%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

What Is Inspirna?

Inspirna is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Inspirna's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016.

keywords:N/A

N/A

Total Funding

40

Number of Employees

$3.1M

Revenue (est)

21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.3M400%$7.5M
#2
$3.2M40-15%N/A
#3
$6.4M40-31%N/A
#4
N/A40-5%N/A
#5
$7M40-29%N/A